HL 036

Drug Profile

HL 036

Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HL036; TNF-alpha blocker - HanAll Biopharma

Latest Information Update: 20 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator HanAll Biopharma
  • Class Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 01 Jun 2016 HanAll BioPharma completes a phase I trial in Dry eyes (In volunteers) in South Korea (Ophthalmic) (NCT02717208)
  • 01 Feb 2016 Phase-I clinical trials in Dry eyes (In volunteers) in South Korea (Ophthalmic) (NCT02717208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top